Summit Therapeutics, Inc. (SMMT)
14.20
+0.58
(+4.26%)
USD |
NASDAQ |
Sep 01, 12:01
Summit Therapeutics Cash from Operations (TTM) : -457.02M for June 30, 2026
Cash from Operations (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | -457.02M |
| March 31, 2026 | -386.99M |
| December 31, 2025 | -325.87M |
| September 30, 2025 | -274.21M |
| June 30, 2025 | -211.31M |
| March 31, 2025 | -173.64M |
| December 31, 2024 | -142.60M |
| September 30, 2024 | -113.42M |
| June 30, 2024 | -96.55M |
| March 31, 2024 | -93.61M |
| December 31, 2023 | -76.61M |
| September 30, 2023 | -54.39M |
| June 30, 2023 | -45.66M |
| March 31, 2023 | -33.73M |
| December 31, 2022 | -39.60M |
| September 30, 2022 | -51.47M |
| June 30, 2022 | -67.99M |
| March 31, 2022 | -69.46M |
| December 31, 2021 | -71.13M |
| September 30, 2021 | -72.13M |
| June 30, 2021 | -66.51M |
| March 31, 2021 | -61.65M |
| Date | Value |
|---|---|
| December 31, 2020 | -49.54M |
| September 30, 2020 | |
| June 30, 2020 | |
| March 31, 2020 | |
| January 31, 2020 | |
| October 31, 2019 | |
| July 31, 2019 | |
| April 30, 2019 | |
| January 31, 2019 | -34.36M |
| October 31, 2018 | -36.82M |
| July 31, 2018 | -45.52M |
| April 30, 2018 | -19.59M |
| January 31, 2018 | -19.78M |
| October 31, 2017 | -19.66M |
| July 31, 2017 | 30.29M |
| April 30, 2017 | 14.24M |
| January 31, 2017 | 15.08M |
| October 31, 2016 | 14.76M |
| July 31, 2016 | -27.90M |
| April 30, 2016 | -28.75M |
| January 31, 2016 | -25.47M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| NovelStem International Corp. | -0.2295M |
| Brainstorm Cell Therapeutics, Inc. | -4.057M |
| Kezar Life Sciences, Inc. | -42.03M |
| Protara Therapeutics, Inc. | -66.13M |
| Clene, Inc. | -15.96M |